New analysis of insurance claims covering more than one million births shows a dramatic shift in prescribing patterns for GLP‑1 medications among American women after delivery. The data, spanning seven years, reveals a 24‑fold increase in postpartum GLP‑1 prescriptions, rising from 0.8 % in the first half of 2018 to 1.9 % by the first quarter of 2025. While the drugs have demonstrated broad health benefits, research into their safety during breastfeeding remains scarce, prompting calls for more targeted studies.
A Rapid Rise in Post‑partum Prescriptions
The surge was documented by researchers at the University of Southern California and presented in a study released on Thursday. Lead author and Schaeffer scholar Sih‑Ting Cai commented, “Postpartum is a critical window for addressing metabolic risk after pregnancy, and we’re seeing GLP-1 use explode in this population.” She added, “Because evidence on GLP-1 exposure during breastfeeding remains limited, rising postpartum initiation warrants further study.”
The investigation examined claims data for over a million births, tracking prescription fills from the moment of delivery through the first few years of motherhood. The figures illustrate a steep upward trajectory, with the proportion of new mothers receiving a GLP‑1 medication climbing steadily each quarter. The growth mirrors trends observed in Denmark, despite differences in healthcare systems and drug pricing, suggesting a broader cultural shift in how clinicians manage postpartum metabolic health.
Which Groups Are Driving the Trend?
The study also identified the clinical groups most responsible for the increase. Women with type 2 diabetes recorded the highest prescription rates, reflecting the established role of GLP‑1 agents in diabetes management. However, the fastest growth was seen among mothers who were obese or overweight before conception. The share of women with gestational diabetes initiating GLP‑1 therapy rose markedly, from 0.4 % in mid‑2021 to 2.7 % by the first quarter of 2025. Gestational diabetes affects roughly 5‑9 % of pregnancies and is linked to higher risks of developing type 2 diabetes and postpartum depression, according to the Centers for Disease Control and Prevention.
Most prescriptions were filled between three and six months after delivery, indicating that clinicians are waiting until the immediate postpartum period has stabilised before introducing the medication. The timing aligns with guidelines that recommend addressing metabolic disturbances once acute recovery is complete, yet it also places the drug in close proximity to the breastfeeding stage for many mothers.
Uncertainties Around Breastfeeding and Infant Safety
Despite the expanding use, the safety profile of GLP‑1 drugs during lactation remains poorly defined. Dr. Jyoti Manekar, an obesity‑medicine specialist at Georgia’s Northside Hospital, warned, “There’s limited safety data in lactating women, and it’s unclear whether the drug is excreted in breast milk or how it might affect a nursing infant’s growth, metabolism or pancreatic development,” she explained. Current recommendations from professional bodies still advise caution, and many clinicians refrain from prescribing GLP‑1 agents to breastfeeding mothers.
A June study led by Harvard T.H. Chan School of Public Health offered a partial reassurance. It found, “Taking the drugs during the first trimester does not appear to substantially increase the risk of adverse outcomes.” However, the research focused on early‑pregnancy exposure and did not address the postpartum lactation period, leaving a critical gap in the evidence base.
The lack of robust data means that both healthcare providers and expectant mothers must weigh potential benefits against unknown risks. For women with pre‑existing diabetes or obesity, the metabolic advantages of GLP‑1 therapy may be compelling, yet the absence of clear lactation safety information creates clinical uncertainty.
Implications for Healthcare and Future Research
The findings have sparked debate among policymakers, clinicians, and patient advocates. Some argue that the rise reflects improved recognition of postpartum metabolic disorders and a willingness to employ effective pharmacologic tools. Others caution that the rapid adoption may outpace the generation of essential safety data, potentially exposing infants to unforeseen consequences.
The study’s authors stress the need for dedicated lactation research, including pharmacokinetic analyses and long‑term developmental outcomes for infants exposed through breast milk. Parallel efforts are underway to compare U.S. prescribing patterns with those in countries like Denmark, where similar increases have been observed but where national health databases enable more comprehensive safety monitoring.
Moreover, the data highlight a broader trend: GLP‑1 medications have become a mainstay for weight management and metabolic health, with more than 30 million Americans now using them. As the population of women of reproductive age continues to include higher rates of obesity and gestational diabetes, clinicians must balance therapeutic enthusiasm with rigorous scientific inquiry.
Why it Matters
The rapid escalation of GLP‑1 prescriptions among new mothers signals a pivotal shift in postpartum care, offering potential metabolic benefits for women at risk of diabetes and obesity. Yet the accompanying paucity of safety data for breastfeeding infants raises urgent ethical and clinical questions. This moment demands that researchers, healthcare systems, and regulators prioritise studies that clarify drug transfer into breast milk and assess long‑term developmental impacts. Only with robust evidence can clinicians provide confident guidance, ensuring that the promise of improved maternal health does not inadvertently compromise infant well‑being. The conversation underscores a larger imperative: advancing medical innovation while safeguarding the most vulnerable members of our society.
